“Myocardial acuumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909”, Nielsen-Kudsk et al., Pharmacology and Toxicology (Oxford, UK), 1990, 66(3), 197-202.* |
“Dopamine Stimulation of Cardiac .beta.-adrenoceptors : the involvement of sympathetic amine transporters and the effect of SKF38393”, British Journal of Pharmacology, 1997, 122/8, 1669-1678.* |
“Effects of cocaine and GBR 12909 on cardiac functioning in rhesus monkeys”, Society for Neuroscience, abstracts, 1998, vol. 24, No. 1-2, pp. 2170.* |
Balser, J. R. et al., “Suppression of time-dependent outward current in guinea pig ventricular myocytes: Actions of quinidine and amiodarone”, Circ. Res. 69:519-529 (1991). |
Funck-Bretano, C. “Rate dependence of class III actions in the heart”, Fundam. Clin. Pharmacol. 7:51-59 (1993). |
Curran, M.E. et al., “A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome”, Cell 80: 795-803 (1995). |
Dutta, A.K. et al., “Positional Importance of the Nitrogen Atom in Novel Piperidine Analogs of GBR 12909: Affinity and Selectivity for the Dopamine Transporter”, Med. Chem. Res. 3:209-222 (1993). |
Hondeghem, L. M., “Development of Class III Antiarrhythmic Agents”, J. Cardiovasc. Pharmacol. (20) (Suppl. 2):S17-S22 (1992). |
Hondeghem, L.M. et al., “Class III antiarrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use dependence”, Circulation, 81:686-690 (1990). |
Jurkiewicz, N.K. et al., “Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III anti-arrhythmic agent: Specific block of rapidly activating delayed rectifier K+ current by dofetilide”, Circ .Res. 72:75-83 (1993). |
Lewis, D.B. et al., “Oxygenated analogues of 1-(2-(diphenylmethoxy) ethyl)- and 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl) piperazines (GBR 12935 and GBR 12909) as Potential Extended-Action Cocaine-Abuse Therapeutic Agents”, J. Med. Chem. 42:5029-5042 (1999). |
Nademanee, K., “The Aminodarone Odyssey”, J. Am. Coll. Cardiol. 20:1063-1065 (1992). |
Roden, D. M. et al., “Current Status of Class III Antiarrhythmic Drug Therapy”, Am. J. Cardiol, 72:44B-49B (1993). |
Sadanaga, T. et al., “Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III anti-arrhythmic agents and their value in predicting efficacy”, Am. Heart J. 126:114-121 (1993). |
Sanguinetti, M.C. et al., “Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by Class III anti-arrythmic agents”, J. Gen. Physiol. 96:195-215 (1990). |
Singh B. N., et al., “The effect of amiodarone, a new anti-anginal drug, on cardiac muscle”, Br. J. Pharmacol 39:657-667 (1970). |
Singh B. N., et al., “A third class of anti-arrhythmic action effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3747”, Br. J. Pharmacol 39:675-687 (1970). |
Williams, E.M.V. et al., “Classification of antiarrhythmic drugs”, Symposium on Cardiac Arrhythmias, (Sandoe E. et al., (Editors)) Chapter 20, pp. 449-472 (1981). |
Maginn et al., “Protective Effects of Vanoxeamine (GBR 12909) Against Ischemia-Induced Hyperactivity and Neurodegeneration in the Gerbil Model of Cerebral Ischemia,”, abstract, Pharmacology, Biochemistry and Behavior, 1997, 56(4), pp. 727-735. |
Nielsen-Kidsk et al., “Myocardial Accumulation Kinetics and Pharmacodynamics in the Isolated Rabit Heart of a New Inhibitor of Dopamine Reuptake, GBR 12909,” abstract, Pharmacology & Toxicology (Oxford, United Kingdom), 1990, 66(3), pp. 197-202. |
Ficker et al., “The Binding Site for Channel Blockers that Rescue Misprocessed Human Long QT Syndrome Type 2 Ether-A-Gogo-Related Gene (HERG) Mutations,” abstract, Journal of Biological Chemistry, 2002, 277(7), pp. 4989-4998. |
Thomas et al., “High-Affinity Blockade of Human Ether-A-Go-Related Gene Human Cardiac Potassium Channels by the Novel Antiarrhythmic Drug BRL-32872,” abstract, Journal of Pharmacology and Experimental Therapeutics, 2001, 297(2), pp. 753-761. |